Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

Embryonal Childhood Rhabdomyosarcoma Clinical Trial

Official title:

Observational - CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01496573
• Other study ID #: ARST12B4
• Secondary ID: NCI-2012-00094
• Status: Completed
• Phase: N/A
• First received: December 16, 2011
• Last updated: May 17, 2016
• Start date: December 2011
• Est. completion date: May 2016

Study information

• Verified date: May 2016
• Source: Children's Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

This research trial studies biomarkers in tumor tissue samples from younger patients with rhabdomyosarcoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

Description:

PRIMARY OBJECTIVES:

I. To demonstrate CRKL expression at the protein level in rhabdomyosarcoma tumors by tissue microarray (TMA).

OUTLINE:

Archived tumor tissue samples are analyzed for CRKL expression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 77
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma specimens from the Children Oncology Group (COG) tumor microarrays (TMAs)

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Alveolar Childhood Rhabdomyosarcoma
• Childhood Rhabdomyosarcoma
• Embryonal Childhood Rhabdomyosarcoma
• Rhabdomyosarcoma

Intervention

Other:
• laboratory biomarker analysis
Correlative studies

Locations

Country	Name	City	State
United States	Children's Oncology Group	Monrovia	California

Sponsors (2)

Lead Sponsor	Collaborator
Children's Oncology Group	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CRKL expression at the protein level		1 month	No